Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aoife M Shannon

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Journal of Pharmacy and Pharmacology|July 23, 2008
Antiangiogenics and radiotherapyAoife M Shannon, Kaye J Williams
Cancer Treatment Reviews|August 21, 2003
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapiesAoife M Shannon, David J Bouchier-Hayes, Claire M Condron, et al.
Cancer Treatment Reviews|August 8, 2006
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expressionJill L O'Donnell, Myles R Joyce, Aoife M Shannon, et al.
Molecular Cancer Therapeutics|February 20, 2007
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefitKaye J Williams, Brian A Telfer, Aoife M Shannon, et al.
Proteomics. Clinical Applications|May 15, 2013
Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapyBrian Morrissey, Carmel O'Shea, John Armstrong, et al.
Molecular Imaging and Biology|November 20, 2013
Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055Heather G Keen, Sally-Ann Ricketts, Juliana Maynard, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2023
Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancerKillian Nugent, Darragh Browne, Mary Dunne, et al.
Cancers|May 14, 2022
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and LegacySeamus O'Reilly, Verena Murphy, Eibhlin Mulroe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenograftsAoife M Shannon, Brian A Telfer, Paul D Smith, et al.
Frontiers in Oncology|March 14, 2025
Detection of radiosensitive subpopulations <i>ex-vivo</i> with Raman microspectroscopyAidan D Meade, Adrian Maguire, Jane Bryant, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Pharmacy and Pharmacology|July 23, 2008
Antiangiogenics and radiotherapyAoife M Shannon, Kaye J Williams
Cancer Treatment Reviews|August 21, 2003
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapiesAoife M Shannon, David J Bouchier-Hayes, Claire M Condron, et al.
Cancer Treatment Reviews|August 8, 2006
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expressionJill L O'Donnell, Myles R Joyce, Aoife M Shannon, et al.
Molecular Cancer Therapeutics|February 20, 2007
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefitKaye J Williams, Brian A Telfer, Aoife M Shannon, et al.
Proteomics. Clinical Applications|May 15, 2013
Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapyBrian Morrissey, Carmel O'Shea, John Armstrong, et al.
Molecular Imaging and Biology|November 20, 2013
Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055Heather G Keen, Sally-Ann Ricketts, Juliana Maynard, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2023
Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancerKillian Nugent, Darragh Browne, Mary Dunne, et al.
Cancers|May 14, 2022
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and LegacySeamus O'Reilly, Verena Murphy, Eibhlin Mulroe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenograftsAoife M Shannon, Brian A Telfer, Paul D Smith, et al.
Frontiers in Oncology|March 14, 2025
Detection of radiosensitive subpopulations <i>ex-vivo</i> with Raman microspectroscopyAidan D Meade, Adrian Maguire, Jane Bryant, et al.
Pageof 2